The Role of Physician Specialty in the Underutilization of Standard-of-Care Treatment Intensification in Patients With Metastatic Castration-sensitive Prostate Cancer-Reference-Cited by-同舟云学术

The Role of Physician Specialty in the Underutilization of Standard-of-Care Treatment Intensification in Patients With Metastatic Castration-sensitive Prostate Cancer

Published:2023-06 Issue:6 Volume:209 Page:1120-1131
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Swami Umang¹^ORCID,Hong Agnes²,El-Chaar Nader N.³,Ramaswamy Krishnan⁴,Diessner Brandon J.⁵,Blauer-Peterson Cori J.⁴,Sandin Rickard⁶,Nimke David³,Agarwal Neeraj¹

Affiliation:

1. Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah

2. Pfizer Inc, New York, New York (formerly at Astellas Pharma Inc, Northbrook, Illinois)

3. Astellas Pharma Inc, Northbrook, Illinois

4. Pfizer Inc, New York, New York

5. Optum, Eden Prairie, Minnesota

6. Pfizer AB, Sollentuna, Sweden

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Link

http://www.auajournals.org/doi/pdf/10.1097/JU.0000000000003370

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Intensification With Novel Hormonal Therapy in Castration-Sensitive Prostate Cancer: Patient Identification and Clinical Rationale;Clinical Genitourinary Cancer;2024-12

2. Real‐world prevalence of adverse events with first‐line systemic therapies among patients with metastatic castration‐sensitive prostate cancer;The Prostate;2024-08-20

3. Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS—Meet-URO 26 Study;Clinical Genitourinary Cancer;2024-08

4. Adverse events in men with advanced prostate cancer treated with androgen biosynthesis inhibitors and androgen receptor inhibitors;JNCI: Journal of the National Cancer Institute;2024-07-25

5. First-line combination treatment with PARP and androgen receptor–signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States;Cancer Treatment Reviews;2024-05